# Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD

> **NCT03903809** · PHASE3 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 175 (actual)

## Conditions studied

- Non-Dialysis-Dependent Chronic Kidney Disease

## Interventions

- **DRUG:** Pegol-Sihematide
- **DRUG:** ESPO

## Key facts

- **NCT ID:** NCT03903809
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-20
- **Primary completion:** 2021-10-14
- **Final completion:** 2022-12-31
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03903809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03903809, "Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03903809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*